Amanta Healthcare544502Quarterly results
Board approves Q2 and H1 unaudited results; auditors' Limited Review Report carries unmodified opinion
Board meeting on Nov 3, 2026 (4:00 PM to 5:00 PM) approved the standalone unaudited financial results for the quarter and half year ended September 30, 2026.
By ScoutQuest · · 3 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8,313.24 | 7,088.73 | +17.3% | 6,880.32 | +20.8% |
| Total income | 8,388.78 | 7,095.80 | +18.2% | 6,944.62 | +20.8% |
| Profit before tax | 682.62 | 227.78 | +200% | 449.23 | +52% |
| Profit after tax | 486.09 | 120.75 | +303% | 331.05 | +46.8% |
| Total comprehensive income | 468.03 | 110.73 | +323% | 312.98 | +49.5% |
| Basic EPS | 1.25 | 0.31 | +303% | 0.85 | +47.1% |
- Total income
- Latest 8,388.78 | Year ago 7,095.80 (+18.2%) | Prev qtr 6,944.62 (+20.8%)
- Profit after tax
- Latest 486.09 | Year ago 120.75 (+303%) | Prev qtr 331.05 (+46.8%)
- Period
- 30.09.2026 Un-audited
Auditor's review
Conclusion: Unmodified
Notes to the results
- Exceptional item: IPO-related cost of Rs. 262.88 lakhs (net of GST) allocated for listing of existing shares recognised in P&L in the year ended March 31, 2026.
- IPO of 10,000,000 shares at Rs. 126 per share raised Rs. 12,600 lakhs; Rs. 10,082.69 lakhs utilised and Rs. 2,517.31 lakhs unutilised as at September 30, 2026.
- Term loans of Rs. 9,191.76 lakhs classified as current liabilities as two lenders hold a call option to recall the loans on April 15, 2027.
Board meeting outcome
- The Board of Directors met on November 3, 2026 from 04:00 P.M. to 05:00 P.M. and approved the Standalone Un-Audited Financial Results for the quarter and half year ended September 30, 2026.
- The Limited Review Report issued by the auditors carries an unmodified opinion.
- The results were reviewed by the Audit Committee and approved by the Board. The company operates in one business segment: manufacturing and sale of pharmaceutical products, including contract manufacturing services.
Quarter ended September 30, 2026 (standalone, unaudited, Rs. in lakhs)
- Revenue from operations: 8,313.24, against 7,088.73 in the quarter ended September 30, 2025
- Total income: 8,388.78, against 7,095.80
- Total expenses: 7,706.16, against 6,605.14
- Profit before tax: 682.62, against 227.78
- Profit for the period: 486.09, against 120.75
- Earnings per share (basic and diluted, Rs.): 1.25, against 0.31
- The September 2025 quarter carried an exceptional item of 262.88 that is not present this quarter.
Half year ended September 30, 2026
- Revenue from operations: 15,193.56, against 13,619.44
- Total income: 15,333.49, against 13,722.60
- Profit before tax: 1,131.85, against 720.43
- Profit for the period: 817.14, against 471.47
- Earnings per share: 2.10, against 1.37
Balance sheet and cash (Rs. in lakhs)
- Total assets: 52,895.06 as at September 30, 2026, against 55,798.07 as at March 31, 2026
- Cash and cash equivalents: 166.60, against 8,101.03
- Non-current borrowings: 4,898.88, against 16,197.06; current borrowings: 14,556.94, against 7,244.75
- Net cash from operating activities in the half year: 2,193.59, against 2,764.93
- Net cash used in investing activities: 4,836.22; net cash used in financing activities: 5,291.80
Loan recall clause
- The company has term loans from two lenders, each of which holds a call option to recall the loan on April 15, 2027.
- Because the company did not have the right at the reporting date to defer settlement for at least twelve months after September 30, 2026, the outstanding amount of 9,191.76 is classified as current liabilities.
- Management does not expect any cash outflow on account of the above.
Where the IPO money stands
- The company completed its Initial Public Offer of 1,00,00,000 equity shares of face value of Rs. 10 each at Rs. 126 per share; the issue comprised 100% fresh issue aggregating to 12,600.00, and the shares were listed on BSE and NSE on September 09, 2025.
- Of the 12,600.00, 10,082.69 had been utilised and 2,517.31 remained unutilised as at September 30, 2026.
- Capital expenditure for the SteriPort line at Haryala, Kheda: 7,000.00 provided for, 6,701.81 used, 298.19 unutilised.
- Capital expenditure for the new line at SVP, Haryala: 3,013.11 provided for, 793.99 used, 2,219.12 unutilised.
- The unutilised portion is held in fixed deposits and a monitoring account; interest accrued on these fixed deposits as at September 30, 2026 was 12.31.
- The company links the delay to deferment of payments to suppliers pending completion of work or supply against agreed milestones, and to pending finalisation of commercial terms for machinery.
- Separately, IPO-related expenses of 1,719.16 (net of GST) for the fresh issue were adjusted against securities premium, and 262.88 (net of GST) for selling shareholders was shown as an exceptional item.
What a retail investor may track
- Earnings: profit for the period stood at 486.09 for the quarter and 817.14 for the half year, with revenue from operations at 8,313.24 and 15,193.56 respectively.
- Cash: cash and cash equivalents moved from 8,101.03 at March 31, 2026 to 166.60 at September 30, 2026, while bank balances other than cash and cash equivalents were 2,513.08.
- Debt timing: the term loans of 9,191.76 sit under current liabilities because of the April 15, 2027 recall option, so refinancing or repayment is a date to keep in view.
- IPO spending: 2,517.31 of the 12,600.00 raised is yet to be spent on the stated objects, with 2,219.12 of it tied to the SVP line.
2,517.31 lakhsIPO proceeds unutilised as at Sep 30
Profit for the period, half year ended Sep 30817.14 lakh
Profit before tax, latest quarter682.62 (Rs. in lakhs)
Profit before tax, quarter449.23 (Rs. in lakhs)
Profit after tax, quarter331.05 (Rs. in lakhs)
Profit before tax, year-ago quarter227.78 (Rs. in lakhs)
Also from Amanta Healthcare
Amanta Healthcare posts audio recording of November 4, 2026 post results conference call on website
4 Nov 2026
CRISIL monitoring report: no deviation in use of IPO proceeds in September 2026 quarter
4 Nov 2026
Amanta Healthcare Q2 FY27: revenue up 17.3% YoY, SteriPort Line 3 commissioned
4 Nov 2026
More numbers
- Revenue from operations, half year ended Sep 30, 202615,193.56 lakh
- Profit for the period, half year ended Sep 30, 2026817.14 lakh
- Earnings per share, half year ended Sep 30, 2026 (basic and diluted)2.10
- Term loans of two lenders classified as current liabilities9,191.76 lakhs
- IPO proceeds unutilised as at Sep 30, 20262,517.31 lakhs
- Total assets as at Sep 30, 202652,895.06 lakh
- Total income, latest quarter8,388.78 (Rs. in lakhs)
- Total income, year-ago quarter7,095.80 (Rs. in lakhs)
- Total income, previous quarter6,944.62 (Rs. in lakhs)
- Total comprehensive income, latest quarter468.03 (Rs. in lakhs)
- Total comprehensive income, year-ago quarter110.73 (Rs. in lakhs)
- Total comprehensive income, previous quarter312.98 (Rs. in lakhs)
- Profit after tax, latest quarter486.09 (Rs. in lakhs)
- Profit after tax, year-ago quarter120.75 (Rs. in lakhs)
- Profit after tax, previous quarter331.05 (Rs. in lakhs)
- Revenue from operations, latest quarter8,313.24 (Rs. in lakhs)
- Revenue from operations, year-ago quarter7,088.73 (Rs. in lakhs)
- Revenue from operations, previous quarter6,880.32 (Rs. in lakhs)
- Profit before tax, latest quarter682.62 (Rs. in lakhs)
- Profit before tax, year-ago quarter227.78 (Rs. in lakhs)
- Profit before tax, previous quarter449.23 (Rs. in lakhs)
Source: BSE · 3 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.